Multi-dimensional Prevention Program After Acute Coronary Syndrome (ELIPS) (SPUM-ACS- SP1)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01075867

Enrollment

2498

Registered

2010-02-25

Start date

2010-04-30

Completion date

2018-12-31

Last updated

2020-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Brief summary

To demonstrate the effectiveness of the ELIPS programme (Multi-dimEnsionaL preventIon Program after Acute coronary Syndrome), which aims at improving quality of care of patients admitted to hospital with Acute Coronary Syndrome (ACS) in the Swiss setting. The program targets an increase in prescription rates by physicians and long term medication adherence and adoption of healthy lifestyle attitudes by patients. The program is dedicated to caregivers to increase their application of guidelines into practice, to increase their confidence in therapeutic education of patients, and to patients to improve their understanding of ACS and its treatment and to increase their motivation for long term treatment,.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients \>18 years * Admitted for an ACS, that is with symptoms compatible with angina pectoris (chest pain, breathlessness) and at least one of the following 3 features : a) Elevation or depression of the ST segment, inverted T waves or dynamic changes in the repolarization phase b) Positive troponin c) Known coronary artery disease. A significant coronary artery disease must be confirmed angiographically.

Exclusion criteria

* Severe physical disability or dement * Less than 1 year of life expectancy for non cardiac reason

Design outcomes

Primary

Measure	Time frame	Description
composite of death and cardiovascular event	1 year	Composite of * death from any cause, * myocardial infarction, * documented unstable angina requiring rehospitalization, * revascularization (performed at least 30 days after randomization), * documented new or worsen lower limb ischemia, * stroke * transient cerebral ischemic accident.

Secondary

Measure	Time frame	Description
Process outcome at discharge	1 year	Prescription of recommended treatment at discharge: * Cardiovascular medication (Lipid lowering treatment, beta-blockers, antithrombotic therapy (acetylsalicylic acid, clopidogrel), ACE-inhibitors, AT-II antagonists) * Smoking cessation counseling during hospital stay * Referral to cardiovascular rehabilitation center * Use of educational booklet at discharge
Clinical outcomes at follow-up	1 year	Individual data on each of the composite outcome Cardiovascular mortality
Surrogate outcomes at follow-up	1 year	Cardiovascular risk factor control at follow-up: * arterial blood pressure, * fasting blood glucose, * blood lipids (LDL-Cholesterol, HDL-Cholesterol, Triglycerides), * smoking cessation (7-days point prevalence at one year and continuous abstinence since hospitalisation) * body mass index reduction * abdominal waist reduction Quality of life and utility (EQ-5D questionnaire) Adherence to medication (MAS questionnaire) Physical activity (IPAQ questionnaire) Motivation to adopt therapeutic lifestyle attitudes (smoking cessation, diet change, physical activity)

Countries

Switzerland

Outcome results